This has more than 12.5 million shares of SXTP stock being traded as of this writing. That's already well above its daily average trading volume of about 757,000 shares. The company's float is only 8.98 million units. What is worth keeping in mind is that SXTP is in penny stock territory. This comes from its low prior closing price of 25 cents and its market capitalization of just $3.003 million. Being a penny stock comes with certain vulnerabilities. That includes being open to volatility. This can happen ...

Company Overview - 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and focuses on developing and marketing new medicines for infectious diseases [1] - The company achieved FDA approval for its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 [1] - 60 Degrees Pharmaceuticals collaborates with prominent research organizations in the U.S., Australia, and Singapore [1] - The company is headquartered in Washington D.C. and has a majority-owned subsidiary in Australia [1] Product Information - ARAKODA® (tafenoquine) is approved for malaria prophylaxis in the U.S. and Australia, with commercial launches occurring in 2019 [6] - Tafenoquine has not been proven effective for the treatment or prevention of babesiosis and is not FDA-approved for this indication [8][11] Recent Developments - The company announced ethics approval for an open label, expanded access study of the ARAKODA® regimen in immunosuppressed patients with persistent/relapsing babesiosis [7] - The goal of the study is to confirm an 80% cure rate for babesiosis observed in a previous case series conducted by Yale School of Public Health [12] - The total accessible market for ARAKODA in babesiosis is estimated at 38,000 acute patients and at least 375,000 chronic patients in the U.S. [10] Clinical Trials - 60 Degrees Pharmaceuticals is advancing multiple clinical trials to establish the safety and efficacy of tafenoquine for babesiosis [14] - The trials include studies for hospitalized acute babesiosis patients, expanded access for persistent disease, and chronic babesiosis [15] - A New Drug Application with the FDA for a supplemental indication for tafenoquine in babesiosis is planned for the second quarter of 2026 [15]

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharmaceuticals" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis. Tafenoquine is approved for malaria prophylaxis in t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 45-2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ until ______ Commission File Number: 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) | Delaware 45-2406880 | | | | --- | --- | --- | ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | 4 ...